论文部分内容阅读
目的分析氨溴特罗口服液在临床上用于治疗支气管肺炎患儿的疗效及安全性。方法 144例0～36个月的婴幼儿支气管肺炎患者,随机分为治疗组72例(氨溴特罗口服液)和对照组72例(盐酸氨溴索塘浆)。观察两组患儿治疗后体温、咳嗽、肺部啰音消失及X线胸片阴影消失情况。结果治疗组、对照组治疗后咳嗽、体温和肺部啰音消失及X线胸片均较治疗前明显减轻(P<0.05)。治疗组治疗7d后,呼吸道症状改善的总有效率高于对照组。结论氨溴特罗口服液对改善支气管肺炎的临床症状疗效显著。
Objective To analyze the efficacy and safety of ambroxol oral solution in the treatment of children with bronchopneumonia. Methods A total of 144 infants with bronchopneumonia from 0 to 36 months were randomly divided into treatment group (72 cases) and ambroxol hydrochloride group (72 cases). Two groups of children were observed after treatment of body temperature, cough, pulmonary rales disappeared and the disappearance of the shadow of X-ray. Results After treatment, the cough, body temperature and the pulmonary rales disappeared and the radiographs of X-ray were significantly reduced in the treatment group and the control group (P <0.05). After 7 days of treatment, the total effective rate of improvement of respiratory symptoms was higher than that of the control group. Conclusion Ambroxol oral solution can improve the clinical symptoms of bronchopneumonia.